A majority of cancer researchers, including our CRC research group, have been focusing on the typical oncogenes, such as KRAS [22], and classic tumor suppressors like TP53 [23], to clarify their significance of various biomarkers in colon cancer. This evidence concerns the gene TP53 and colonic neoplasm.